Treatment of rheumatoid arthritis with etanercept

Mark C Genovese; Joel M Kremer

doi:10.1016/j.rdc.2004.01.004

Treatment of rheumatoid arthritis with etanercept

Rheum Dis Clin North Am. 2004 May;30(2):311-28, vi-vii. doi: 10.1016/j.rdc.2004.01.004.

Authors

Mark C Genovese¹, Joel M Kremer

Affiliation

¹ Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA. [email protected]

PMID: 15172043
DOI: 10.1016/j.rdc.2004.01.004

Abstract

Etanercept is effective in the treatment of rheumatoid arthritis (RA)when used as monotherapy and in combination with methotrexate(MTX). Radiographic progression of disease was slowed significantly when the drug was used for a 24-month period and was statistically significantly better than MTX. In addition to its use in RA,etanercept is approved by the U.S. Food and Drug Administration for other rheumatologic conditions, including psoriatic arthritis,ankylosing spondylitis, and juvenile chronic arthritis.

Publication types

Review

MeSH terms

Antirheumatic Agents / adverse effects
Antirheumatic Agents / pharmacology
Antirheumatic Agents / therapeutic use*
Arthritis / drug therapy
Arthritis, Rheumatoid / drug therapy*
Etanercept
Granulomatosis with Polyangiitis / drug therapy
Humans
Immunoglobulin G / adverse effects
Immunoglobulin G / pharmacology
Immunoglobulin G / therapeutic use*
Receptors, Tumor Necrosis Factor / therapeutic use*

Substances

Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Etanercept